Article
Medicine, Research & Experimental
Elena Gkrouzman, Rohan Willis, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz-Irastorza, H. Michael Belmont, Paul R. Fortin, Maria Gerosa, Flavio Signorelli, Tatsuya Atsumi, D. Ware Branch, Cecilia Nalli, Esther Rodriguez-Almaraz, Michelle A. Petri, Ricard Cervera, Jason S. Knight, Maria Efthymiou, Hannah Cohen, Maria Laura Bertolaccini, Doruk Erkan, Robert Roubey
Summary: A study found that different profiles of antiphospholipid antibody (aPL) are associated with the clinical manifestations of antiphospholipid syndrome (APS), particularly higher levels of anticardiolipin antibody (aCL) and anti -b2 glycoprotein-I antibody (ab2GPI). The study also identified overlapping antibody detection methods and proposed a calculation method to assess the overall burden of aPL.
LABORATORY INVESTIGATION
(2023)
Review
Biochemistry & Molecular Biology
Ilaria Mormile, Francescopaolo Granata, Alessandra Punziano, Amato de Paulis, Francesca Wanda Rossi
Summary: Antiphospholipid syndrome is characterized by thrombosis and pregnancy complications in patients with antiphospholipid antibodies. Lifelong anticoagulation is the main therapy, but immunosuppressant drugs may offer new options for managing associated complications.
Article
Rheumatology
Selcan Demir, Jessica Li, Laurence S. Magder, Michelle Petri
Summary: The study showed that LA remained the best predictor of thrombosis in SLE patients, and adding additional aPL did not increase the risk except for anti-beta(2)-glycoprotein I IgA.
Review
Medicine, General & Internal
Arne Vandevelde, Katrien M. J. Devreese
Summary: The diagnosis and risk stratification of antiphospholipid syndrome (APS) are complex and require various laboratory tests. Efforts to standardize and optimize these tests are ongoing to improve diagnostic accuracy and repeatability. There are challenges in laboratory testing, such as interference by anticoagulation therapy for LAC detection and high variability due to different reagents and detection techniques.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Gustavo G. M. Balbi, Yasaman Ahmadzadeh, Maria G. Tektonidou, Vittorio Pengo, Savino Sciascia, Amaia Ugarte, H. Michael Belmont, Chary Lopez-Pedrera, Paul R. Fortin, Denis Wahl, Maria Gerosa, Guilherme R. de Jesus, Lanlan Ji, Tatsuya Atsumi, Maria Efthymiou, D. Ware Branch, Cecilia Nalli, Esther Rodriguez Almaraz, Michelle Petri, Ricard Cervera, Jason S. Knight, Bahar Artim-Esen, Rohan Willis, Maria Laura Bertolaccini, Hannah Cohen, Robert Roubey, Doruk Erkan, Danieli Castro Oliveira de Andrade
Summary: The objective of this study was to quantify the damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis, and to identify clinical and laboratory characteristics associated with damage in these patients. The study found that DIAPS is of great significance in identifying patients with a higher damage burden and selected traditional cardiovascular risk factors, steroid use, and specific aPL profiles may help in identifying these patients.
Article
Rheumatology
Amaia Ugarte, Alazne Garcia de Bustos, Ioana Ruiz-Arruza, Adriana Soto-Peleteiro, Daniel Martin-Iglesias, Cristina Gonzalez-Echavarri, Guillermo Ruiz-Irastorza
Summary: This study compared the influence of aPLs on global and cardiovascular damage in patients with SLE diagnosed before and after the year 2000. The results showed that the effects of aPL on damage accrual in SLE patients have been reduced over recent years, possibly due to the widespread use of HCQ and improved thromboprophylaxis.
Review
Biochemistry & Molecular Biology
Sonia Guadalupe Barreno-Rocha, Sandra Guzman-Silahua, Sinai-del-Carmen Rodriguez-Davila, Guadalupe Estela Gavilanez-Chavez, Ernesto German Cardona-Munoz, Carlos Riebeling-Navarro, Benjamin Rubio-Jurado, Arnulfo Hernan Nava-Zavala
Summary: Phospholipids, a main type of lipids involved in cell membrane formation, are essential for tumor cell survival. Antiphospholipid antibodies target phospholipids in cell membranes and have been found to be present in hematological neoplasms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Tessa Noordermeer, Jessica E. Molhoek, Roger E. G. Schutgens, Silvie A. E. Sebastian, Sandra Drost-Verhoef, Annet C. W. van Wesel, Philip G. de Groot, Joost C. M. Meijers, Rolf T. Urbanus
Summary: Anti-beta 2GPI and anti-prothrombin antibodies cause lupus anticoagulant (LA) through different mechanisms: anti-beta 2GPI antibodies interfere with FV activation by FXa through a direct interaction, while anti-prothrombin antibodies compete with FXa for phospholipid binding sites.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Immunology
Katarina Kmet'ova, Elena Lonina, Srilakshmi Yalavarthi, Jerrold S. Levine, Claire K. Hoy, Cyrus Sarosh, Kelsey Gockman, Alexandra E. Morris, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Rebecca Subang, Joyce Rauch, Jason S. Knight
Summary: β2GPI can bind not only to phospholipids, but also to cell-free DNA and neutrophil extracellular traps (NETs). The study showed that β2GPI interacts with cell-free DNA and NETs in a dose-dependent manner, retarding their migration. The authors also demonstrated the presence of β2GPI-DNA complexes in the plasma of APS patients, suggesting a potential role of this interaction in autoimmunity.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Li Wu, Xuhui Fang, Fangting Lu, Yu Zhang, Yanshi Wang, Joanne Kwak-Kim
Summary: This study aimed to evaluate the effects of anticardiolipin (aCL) and/or anti-beta 2-glycoprotein-I (a beta 2GPI) antibodies, known as antiphospholipid antibodies (aPL), on in vitro fertilization (IVF) outcomes. The results showed that infertile women with aPL had worse outcomes in terms of oocyte quality, embryo quality, and implantation capacity. Imbalanced T cell subset ratios and elevated levels of certain cytokines were noticed in these women compared to controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tatiana Reshetnyak, Fariza Cheldieva, Maria Cherkasova, Alexander Lila, Evgeny Nasonov
Summary: This study investigates the role of IgA antibodies to cardiolipin (aCL) and IgA antibodies to beta-2 glycoprotein 1 (anti-beta(2)-GP1) in the development of vascular complications in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The results show that the levels of IgA aCL and IgA anti-beta(2)-GP1 are significantly higher in APS patients compared to SLE patients and the control group. These antibodies are closely associated with thrombosis in APS, demonstrating high specificity but low sensitivity for the diagnosis of APS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Fan-Yu Chen, Chun-Fan Chen, Ann Charis Tan, Chia-Hao Chan, Fu-An Chen, Wen-Sheng Liu, Tz-Heng Chen, Shuo-Ming Ou, Szu-Yuan Li, Ming-Tsun Tsai, Yung-Tai Chen, Chih-Ching Lin
Summary: Patients with systemic lupus erythematosus (SLE) have a higher incidence of arteriovenous fistula or graft (AVF/AVG) dysfunction during long-term follow-up, necessitating regular monitoring to improve vascular access function.
SCIENTIFIC REPORTS
(2021)
Review
Biochemistry & Molecular Biology
Ilenia Calcaterra, Pasquale Ambrosino, Nicoletta Vitelli, Roberta Lupoli, Roberta Clara Orsini, Martina Chiurazzi, Mauro Maniscalco, Matteo Nicola Dario Di Minno
Summary: Antiphospholipid antibodies are autoantibodies directed against plasma proteins with affinity for membrane phospholipids, and they play a key role in the development of antiphospholipid syndrome. Risk factors for future thrombotic events in asymptomatic carriers include LA activity, multiple aPL positivity, high-titer aPL, and concomitant systemic autoimmune disease. Carriers of aPL are also at risk for accelerated atherosclerosis and increased cardiovascular risk. Risk stratification is recommended to prevent thrombotic complications in aPL-positive subjects.
Article
Rheumatology
Vineeta Shobha, Liza Rajasekhar, Sandra Manuel, V. Nayana, Chengappa Kavadichanda, Deepika Kounassegarane, Ashish J. Mathew, Ranjan Gupta, Manish Rathi, Parasar Ghosh, Saumya Ranjan Tripathy, Bidyut Das, Sumithra Selvam, Abhishek Kumar Singh, Ankita Singh, Avinash Jain, Amita Aggarwal
Summary: This study aimed to investigate the prevalence, clinical associations, and impact on mortality of antiphospholipid antibodies (APLA) in systemic lupus erythematosus (SLE) patients from India. The study found that about one-third of SLE patients in India have APLA, and its presence is associated with non-criteria hematologic manifestations, arterial thrombosis, and higher mortality rate.
RHEUMATOLOGY INTERNATIONAL
(2023)
Review
Medicine, Research & Experimental
Claudia Mihaela Gavris, Laurentiu Danut Nedelcu, Alina Mihaela Pascu
Summary: Antiphospholipid syndrome (APS) is recognized as a systemic autoimmune disease and a major acquired thrombophilia that affects various vascular territories, with unpredictable evolution in terms of thrombotic events. Proper stratification of thrombotic risk in patients with APS should include classic biological markers, phenotype assessment, and genetic determinants. New non-conventional serological markers, along with genetic risk factors for thrombosis, are gaining importance in thrombotic risk evaluation in APS patients.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)